Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $122.13 billion
- Book Value:
- Revenue TTM:
- $26.32 billion
- Operating Margin TTM:
- Gross Profit TTM:
- $19.92 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Amgen Inc had its IPO on 1983-06-17 under the ticker symbol AMGN.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. Amgen Inc has a staff strength of 25,200 employees.
Shares of Amgen Inc opened at $233.57 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $228.52 - $233.81, and closed at $229.79.
This is a -2.04% slip from the previous day's closing price.
A total volume of 7,817,000 shares were traded at the close of the day’s session.
In the last one week, shares of Amgen Inc have increased by +1.77%.
Amgen Inc's Key Ratios
Amgen Inc has a market cap of $122.13 billion, indicating a price to book ratio of 39.6029 and a price to sales ratio of 5.4945.
In the last 12-months Amgen Inc’s revenue was $26.32 billion with a gross profit of $19.92 billion and an EBITDA of $13.49 billion. The EBITDA ratio measures Amgen Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Amgen Inc’s operating margin was 38.25% while its return on assets stood at 9.97% with a return of equity of 126.47%.
In Q4, Amgen Inc’s quarterly earnings growth was a negative -10.9% while revenue growth was a negative 0.1%.
Amgen Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $12.1 per share while it has a forward price to earnings multiple of 14.9477 and a PEG multiple of 1.5503. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Amgen Inc’s profitability.
Amgen Inc stock is trading at a EV to sales ratio of 6.5285 and a EV to EBITDA ratio of 13.848. Its price to sales ratio in the trailing 12-months stood at 5.4945.
Amgen Inc stock pays annual dividends of $7.76 per share, indicating a yield of 3.73% and a payout ratio of 44.94%.
Balance sheet and cash flow metrics
- Total Assets
- $65.12 billion
- Total Liabilities
- $15.69 billion
- Operating Cash Flow
- Capital Expenditure
- $340 million
- Dividend Payout Ratio
Amgen Inc ended 2023 with $65.12 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $65.12 billion while shareholder equity stood at $3.66 billion.
Amgen Inc ended 2023 with $0 in deferred long-term liabilities, $15.69 billion in other current liabilities, 32514000000.00 in common stock, $-18048000000.00 in retained earnings and $15.53 billion in goodwill. Its cash balance stood at $7.63 billion and cash and short-term investments were $9.31 billion. The company’s total short-term debt was $1,591,000,000 while long-term debt stood at $37.35 billion.
Amgen Inc’s total current assets stands at $22.19 billion while long-term investments were $0 and short-term investments were $1.68 billion. Its net receivables were $5.56 billion compared to accounts payable of $1.57 billion and inventory worth $4.93 billion.
In 2023, Amgen Inc's operating cash flow was $-3473000000.00 while its capital expenditure stood at $340 million.
Comparatively, Amgen Inc paid $0.45 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Amgen Inc stock is currently trading at $229.79 per share. It touched a 52-week high of $292.065 and a 52-week low of $292.065. Analysts tracking the stock have a 12-month average target price of $258.76.
Its 50-day moving average was $245.29 and 200-day moving average was $248.26 The short ratio stood at 2.81 indicating a short percent outstanding of 0%.
Around 20.9% of the company’s stock are held by insiders while 7993.9% are held by institutions.
Frequently Asked Questions About Amgen Inc
Similar Industry Stocks (Drug Manufacturers-General)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.